复方抗肝纤维化处方的优化  

Optimization of a compound prescription for treating liver fibrosis

作　　者：黄亮[1] 漆林艳[1] 陈志良[1] 李亦蕾[1] 文志勇[1] 

机构地区：[1]南方医科大学南方医院药学部药材科,广东广州510515

出　　处：《南方医科大学学报》2012年第1期106-108,共3页Journal of Southern Medical University

基　　金：广东省自然科学基金(S2011010003868)

摘　　要：目的优化处方,以期得到疗效确切,低毒的抗肝纤维化复方。方法运用硫代乙酰胺诱导大鼠肝纤维化模型,采用均匀设计法(二因素五水平)分组实验,并设有正常组,模型组,以大鼠肝组织羟脯氨酸含量作为检测指标,经均匀设计软件3.0处理分析得最佳处方;运用相同方法诱导大鼠肝纤维化模型,设正常组,模型组,秋水仙碱组,最佳处方组,通过观察肝组织羟脯氨酸含量,大鼠血清HA,ALT,AST,ALB含量以及肝组织纤维化变化,对于最佳处方的疗效进行比较和验证实验。结果经实验筛选的最佳处方为甘草甜素70 mg/kg,苦参碱70 mg/kg;验证实验中,最佳处方组抗肝纤维化作用显著(P<0.05),与秋水仙碱组无显著性差异(P>0.05)。结论均匀设计在处方优化中作用显著,明显减少实验次数,结果可靠;苦参碱与甘草甜素合用抗肝纤维化作用明显。Objective To optimize a compound prescription for treatment of liver fibrosis with an improved therapeutic effect and low toxicity.Methods In rat models of liver fibrosis induced by thioacetamide（TAA）,the optimized prescription was screened based on a uniform design with 2-factor 5-level table using Uniform Design 3.0 software and tested using liver content of Hyp as the screening index.To verify the efficacy of the optimized prescription,the rat models of liver fibrosis were randomized into normal control group,model group,colchicine group and optimized prescription group,and the changes of hepatic Hyp content,serum HA,ALT,AST,and ALB levels,and the pathology liver fibrosis were observed after corresponding treatments.Results The optimized prescription,which contained 70 mg/kg glycyrrhizin and 70 mg/kg matrine,showed a significant therapeutic effect against liver fibrosis in rats（P0.05）,and the effect was equivalent to that of colchicine（P0.05）.Conclusion Uniform design is a valuable method in prescription optimization.The optimized compound prescription of matrine and glycyrrhizin has a significant effect in inhibiting liver fibrosis.

关 键 词：均匀设计 肝纤维化 甘草甜素 苦参碱 

分 类 号：R285.5[医药卫生—中药学]